Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics

Frontiers in Bioscience

Volumn 16, Issue 7, 2011, Pages 2671-2681

  Tang, Wei ^a   Shi, Yong Quan ^a   Zou, Jun Jie ^a   Chen, Xiang Fang ^a   Zheng, Jiao Yang ^a   Zhao, Shu Wei ^a   Liu, Zhi Min ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CLINPROT; Diabetic peripheral neuropathy; Diagnostic model; Magnetic beads; Serum

Indexed keywords

APOLIPOPROTEIN C1; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOMICS;

ADULT; AGED; APOLIPOPROTEIN C-I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79959555269     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3879     Document Type: Article

References (25)

1. Andrew JM, Boulton, Rayaz AM, Joseph CA and Jay MS. Diabetic Somatic Neuropathies. Diabetes Care, 27: 1458-86. (2004)
2. Bruce AP, Douglas AG and Vera Bril. Glycemic Control Is Related to the Morphological Severity of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 24: 748-52. (2001) (Pubitemid 32888859)
3. Robert D, Searle, Matthew P, Simpson, Karen H Simpson, Richard Milton and Michael I Bennett. Can chronic neuropathic pain following thoracic surgery be predicted during the postoperative period? Interactive Cardio Vascular and Thoracic Surgery, 9: 999-1002. (2009)
4. Liotta LA, Ferrari M and Petricoin E. Clinical proteomics: Written in blood. Nature, 425:905-12. (2003)
5. Anderson NL, Anderson NG and Mol Cell. Proteome and proteomics: New technologies, new concepts and new words. Proteomics, 1:845-67. (2002)
6. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro V, Steinberg S, Mills G, Simone C, Fishman D, Kohn EC and Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577. (2002) (Pubitemid 34178440)
7. Hilario M, Kalousis A, Muller M and Pellegrini C. Machine learning approaches to lung cancer prediction from mass spectra. Proteomics 3:1716-1719. (2003) (Pubitemid 37129818)
8. Kozak KR, Amneus MW, Pusey SM, Su Feng, Luong MN, Luong SA, Reddy ST and Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange Protein Chips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 100:12343-12348. (2003) (Pubitemid 37271562)
9. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z and Wright GL, Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62(13):3609-14. (2002) (Pubitemid 34728833)
10. Petricoin III EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Christian Trucco, Laura Wiegand, Kamillah Wood, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC and Liotta LA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 94(20):1576-8. (2002) (Pubitemid 35277282)
11. Rai AJ, Zhang Z, Rosenzweig J, Shih LM, Pham TP, Fung ET, Sokoll LJ and Chan DW. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med, 126(12):1518-26. (2002)
12. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts J, Edgerton M, Gonzalez A and Nadaf S, Moore JH, Caprioli RM and Carbone DP. Proteomic patterns of tumor subsets in non-small-cell lung cancer. Lancet, 362(9382):433-9. (2003) (Pubitemid 36999706)
13. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic, 3(4):322-31. (2005) (Pubitemid 40468216)
14. Coombes KR, Morris JS, Hu J, Edmonson SR and Baggerly KA. Serum proteomics profiling - A young technology begins to mature. Nat Biotechnol, 23(3):291-2. (2005) (Pubitemid 41094414)
15. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer, 4(4):309-14. (2004) (Pubitemid 38525286)
16. Boguski MS and McIntosh MW. Biomedical informatics for proteomics. Nature, 422(6928):233-7. (2003) (Pubitemid 36362761)
17. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer, 4(4):309-14. (2004) (Pubitemid 38525286)
18. Somorjai RL, Dolenko B, Baumgartner R. Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: Curses, caveats, cautions. Bioinformatics 2003; 19(12):1484-91. (Pubitemid 37045318)
19. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J Natl Cancer Inst, 96(5):353-6. (2004) (Pubitemid 38351297)
20. Dan Ziegler. Polyneuropathy in the diabetic patient-Update on pathogenesis and management. Nephrol Dial Transplant, 19: 2170-5. (2004) (Pubitemid 39214106)
21. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol, 12: 297-304. (2001) (Pubitemid 32521955)
22. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 19:472-84. (1999)
23. Jong MC, Dahlmans VEH, van Gorp PJJ, van Dijk KW, Breuer ML and Hofker MH. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptorassociated protein-sensitive pathway. J Clin Invest, 98: 2259-67. (1996) (Pubitemid 26394199)
24. Muurling M, Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM and Voshol PJ. Overexpression of APOC1 in obob mice leads to hepatic steatosis and severe hepatic insulin resistance. Journal of lipid research, 45(1): 9-16. (2004) (Pubitemid 38176610)
25. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu Tirgoviste C, Witte DR and Fuller JH. Vascular risk factors and diabetic neuropathy. N Engl J Med, 352(4):341-50. (2005)